This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

40/100

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Prevention trials

Topic: Risk, prevention and care in population studies

The growing prevalence of dementia emphasizes the need for effective prevention strategies. Although the partial efficacy of multidomain interventions for dementia prevention has been demonstrated, understanding the characteristics of individuals who benefit most from these interventions is crucial for optimizing resource allocation. This study investigated the association between participants’ genetic backgrounds and the effectiveness of multidomain interventions for preventing dementia. This study utilized data from the Japan-Multimodal Intervention Trial for the Prevention of Dementia (J-MINT), where older adults with mild cognitive impairment underwent 18 months of multidomain intervention. The intervention included exercise, nutrition, cognitive stimulation, social participation, and vascular risk management. Participants who completed the J-MINT intervention and had genetic data, including whole-genome sequencing (WGS), were analyzed. Using Japanese polygenic risk scores (PRSs) for Alzheimer’s disease, participants were stratified into high- and low-genetic-risk groups. Cognitive composite score (CPS) improvement rates at 6-, 12-, and 18-months were compared between intervention and control groups, with subgroup analyses performed by age (< 75 and $$\ge$$ 75 years). Additionally, a comprehensive variant analysis using WGS was conducted to identify genetic signals potentially associated with the intervention’s effectiveness. Among 289 participants analyzed (168 aged < 75 years; 121 aged ≥ 75 years), 99 were classified into the high-risk PRS group (56 intervention, 43 control) and 190 into the low-risk PRS group (92 intervention, 98 control). For participants aged ≥ 75 years, no statistically significant differences in CPS improvement rates were observed between the intervention and control groups, regardless of PRS classification. However, in participants aged < 75, those in the high-risk PRS group showed significant CPS improvement at the 6-month follow-up. Additionally, analysis of 9,978,605 genetic variants identified two loci, ID3 and LMO1 (rs2067053 and rs201082658), with suggestive associations (P < 1 × 10⁻4) to reduced intervention effectiveness. This study highlighted the utility of PRS in predicting cognitive improvement following multidomain interventions and identified genetic variants that may influence the intervention's effectiveness. The findings provide a valuable foundation for personalized dementia prevention strategies.

Key findings

Although the partial efficacy of multidomain interventions for dementia prevention has been demonstrated, understanding the characteristics of individuals who benefit most from these interventions is crucial for optimizing resource allocation.
Additionally, a comprehensive variant analysis using WGS was conducted to identify genetic signals potentially associated with the intervention’s effectiveness.
For participants aged ≥ 75 years, no statistically significant differences in CPS improvement rates were observed between the intervention and control groups, regardless of PRS classification.
However, in participants aged < 75, those in the high-risk PRS group showed significant CPS improvement at the 6-month follow-up.

Why it matters

This study examined whether genetic background affects how much people with mild cognitive impairment benefit from a multidomain intervention, and found no statistically significant differences in cognitive improvement for participants aged 75 or older. It does not show that the intervention prevents dementia, and the authors are still identifying who benefits most.

New to this subject? Start with our plain-English guide: Prevention →

Study details

Participants289
Evidence strengthLow

How this study scored 40/100

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 38 of the 96 points we could judge it on, which is 40 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy)
Journal's citation record	1 / 4	Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	289 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 3 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	1.0 citations a year over 3 year(s) since 2025
Impact for its field and year	2 / 6	Cited 1.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	0 / 3	Hiroshima University: institution h-index 594 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40490801)
Free to read	2 / 2	Free to read
Points	38 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 38 of the 96 points we could judge it on is 40 out of 100.
Total	40 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Fujita, K., Kimura, T., Yamakawa, A., Niida, S., Ozaki, K., Sakurai, T., et al. (2025). Genetic background and multidomain interventions in mild cognitive impairment. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01764-0

Vancouver

Fujita K, Kimura T, Yamakawa A, Niida S, Ozaki K, Sakurai T, et al. Genetic background and multidomain interventions in mild cognitive impairment. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01764-0. PMID: 40490801.

BibTeX

@article{fujita2025-40490801,
  author  = {Fujita, Kosuke and Kimura, Tetsuaki and Yamakawa, Akiko and Niida, Shumpei and Ozaki, Kouichi and Sakurai, Takashi and Arai, Hidenori and Shigemizu, Daichi and others},
  title   = {{Genetic background and multidomain interventions in mild cognitive impairment}},
  journal = {Alzheimer s Research \& Therapy},
  year    = {2025},
  doi     = {10.1186/s13195-025-01764-0},
  pmid    = {40490801},
  url     = {https://doi.org/10.1186/s13195-025-01764-0}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Prevention trials

Similar studies

More on Prevention trials

See all studies in Prevention trials →